BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21446005)

  • 1. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.
    Robert G; Smit F; Hessels D; Jannink S; Karthaus HF; Aalders T; Jansen K; de la Taille A; Mulders PF; Schalken JA
    Prostate; 2011 Nov; 71(15):1701-9. PubMed ID: 21446005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
    Shafiee R; Shariat A; Khalili S; Malayeri HZ; Mokarizadeh A; Anissian A; Ahmadi MR; Hosseini E; Naderafif M; Mohsenzadeh S; Rasoulian MH; Rezapour R; Pourzaer M
    Tumour Biol; 2015 Apr; 36(4):2437-45. PubMed ID: 25420908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
    Tekin A; Yuksel A; Tekin S; Gumrukcu G; Aslan AR; Sengor F
    J Urol; 2009 Aug; 182(2):564-8; discussion 568-9. PubMed ID: 19524953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation.
    Vignozzi L; Gacci M; Cellai I; Santi R; Corona G; Morelli A; Rastrelli G; Comeglio P; Sebastanelli A; Maneschi E; Nesi G; De Nunzio C; Tubaro A; Mannucci E; Carini M; Maggi M
    Prostate; 2013 Jun; 73(8):789-800. PubMed ID: 23620238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of NKX3.1 in benign prostatic hyperplasia.
    Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
    Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia.
    Liu L; Li Q; Han P; Li X; Zeng H; Zhu Y; Wei Q
    Urology; 2009 Aug; 74(2):340-4. PubMed ID: 19464042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).
    Gandaglia G; Briganti A; Gontero P; Mondaini N; Novara G; Salonia A; Sciarra A; Montorsi F
    BJU Int; 2013 Aug; 112(4):432-41. PubMed ID: 23650937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
    De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
    Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
    Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
    Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.
    Cheng HL; Huang HJ; Ou BY; Chow NH; Chen YW; Tzai TS; Wu CJ; Chen SH
    Proteomics Clin Appl; 2011 Apr; 5(3-4):121-32. PubMed ID: 21322116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
    Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
    Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The relationship between anaphylatoxin C3a and benign prostatic hyperplasia with inflammation].
    Xie L; Cheng SL; Li YZ; Liu LR; Han P; Chen N; Wei Q; Zhou Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 42(5):642-5. PubMed ID: 22007489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules].
    Manzarbeitia F; Vela Navarrete R; Fernández-Aceñero MJ
    Actas Urol Esp; 2010 Jun; 34(6):549-54. PubMed ID: 20510119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could inflammation be a key component in the progression of benign prostatic hyperplasia?
    Kramer G; Marberger M
    Curr Opin Urol; 2006 Jan; 16(1):25-9. PubMed ID: 16385197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
    Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
    Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.